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BACKGROUND

•To examine the impacts of acute mitoquinol mesylate
intake on endothelial function (flow-mediated dilation,
FMD), resting heart rate (RHR), blood pressure (BP),
arterial stiffness (pulse-wave velocity, PWV; augmentation
index, AIx), and exercise tolerance in patients with PAD
•It was hypothesized that acute mitoquinol intake would
improve vascular function and exercise tolerance in these
patients

METHODS
•In 2 study visits, 10 patients with PAD (stage II-III, 5
males) received either mitoquinol mesylate (80 mg) or
placebo (PL, similar in appearance and taste) in a
randomized crossover study design
•At each visit measurements of height, weight, body
composition, hand grip strength, RHR, BP, brachial and
popliteal FMD, PWV, AIx, maximal walking capacity, and
time to claudication onset (COT) were measured before
and after mitoquinol and placebo intake
•Data were analyzed using a 2 x 2 repeated measures
analysis of variance (ANOVA). A probability of type I error
less than 5% (p < 0.05) was considered significant, and
paired t-tests were used for pos hoc comparisons

RESULTS
†
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RESULTS

Age, y
Height, cm
Body mass, kg
BMI, kg/m^2
Body fat, %
R handgrip strength, kg
L handgrip strength, kg

Mitoquinol (n=10)
66.1 ±
10.5
13.8
163.5 ±
79.7 ±
19.3
29.9 ±
6.7
37.6 ±
8.6
32.0 ±
12.8
28.0 ±
11.2

Table 2. Participant characteristics at both the placebo (n=10) and mitoquinol (n=10)
visits. Values are Mean ± SEM.

Placebo (n=10)
Pre
Post
68.2 ± 4.8 67.7 ± 4.3
RHR, bpm
134.6 ± 5.2 135.1 ± 5.4
Systolic BP, mmHg
80.8 ± 2.6 81.4 ± 2.6
Diastolic BP, mmHg
9.2 ± 0.3 9.3 ± 0.3
Carotid-to-radial PWV, m/s
10.4 ± 0.5 10.3 ± 0.5
Carotid-to-ankle PWV, m/s
Carotid-to-femoral PWV, m/s 9.7 ± 0.8 9.7 ± 0.9
685.9 ± 61.2 675.7 ± 61.9
Deceleration time, ms
683.6 ± 43.4 720.9 ± 67.9
Max dP/dt, mmHg/s
47.4 ± 4.5 47.5 ± 4.7
Peripheral PP, mmHg
43.5 ± 4.3 44.6 ± 4.4
Central PP, mmHg
21.9 ± 13.6 21.7 ± 14.1
AP, mmHg
19.7 ± 3.5 21.5 ± 4.5
AIx, mmHg
457.2 ± 35.7 435.2 ± 35.7
Max walking time, s

Mitoquinol (n=10)
Pre
Post
69.3 ± 4.2 66.7 ± 3.6
133.3 ± 5.3 130.6 ± 5.0
82.9 ± 2.5 79.8 ± 2.7
9.2 ± 0.4 9.4 ± 0.4
10.3 ± 0.5 9.5 ± 0.6
10.0 ± 0.7 9.9 ± 0.7
674.2 ± 50.0 650.8 ± 77.2
668.2 ± 65.4 669.4 ± 49.9
47.9 ± 4.3 49.9 ± 4.7
41.5 ± 4.0 40.1 ± 3.9
20.8 ± 12.9 21.1 ± 12.9
21.1 ± 3.5 20.7 ± 4.8
442.7 ± 52.6 516.5 ± 47.1
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Table 1. Participant characteristics at both the placebo (n=10) and mitoquinol (n=10) visits.
Values are Mean ± SD.

Placebo (n=10)
66.1 ±
10.5
13.8
163.5 ±
80.1 ±
19.7
30.0 ±
6.8
37.4 ±
8.5
33.0 ±
13.3
28.4 ±
11.5
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Figure 1. Brachial artery FMD (%)
pre- and post-PL and mitoquinol
intake (n=10)
Values are presented as Mean±SEM
*p<0.05 vs. Pre, † p<0.05 vs. placebo
800

*

Pre
Post

10

*

Pre

Leg FMD (%)

Flow-mediated dilation assessment with doppler ultrasound (left). Pulse-wave velocity
assessment with applanation tonometry (center). Maximal walking test (right).
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Figure 2. Popliteal artery FMD
(%) pre- and post-PL and
mitoquinol intake (n=7)
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PURPOSE

METHODS

Max walking distance (m)

• Peripheral arterial disease (PAD) is an atherosclerotic
disease in the leg arteries which results in reduced blood
perfusion in the leg skeletal muscle and causes leg pain
•Vascular dysfunction and leg pain in patients with PAD may
in part due to endothelial dysfunction, which may be result
from attenuated mitochondrial function and excessive
mitochondria-produced reactive oxygen species (ROS) in
the vascular endothelial cells
•Previous studies have shown that mitoquinol mesylate, a
mitochondrial-targeted antioxidant, can improve both
vascular endothelial and mitochondrial function in older
adults and animal models, however the impacts of
mitoquinol mesylate on vascular function in patients with
PAD have not been elucidated
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Figure 3. Maximal walking distance (m)
pre- and post-PL and mitoquinol intake
(n=8)
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Figure 4. COT (s) during the
maximal walking test pre- and postPL and mitoquinol intake (n=8)

CONCLUSIONS
•Mitoquinol mesylate intake may be an effective therapeutic
strategy for targeting mitochondrial-derived ROS, which may be
useful for treating endothelial dysfunction, leg pain, and
improving walking time in patients with PAD
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